Characterizing the molecular and clinical implications of NRG1 fusions in NSCLC through integrated RNA and DNA sequencing analysis.

Abstract excerpt

NRG1 fusions are oncogenic drivers in non-small cell lung cancer (NSCLC), with therapeutic relevance highlighted by the FDA's designation of Zenocutuzumab for NRG1 fusion-positive cases. However, the molecular and clinical features of different NRG1 fusion types remain unclear. We retrospectively analyzed 435 NSCLC patients (78 NRG1 fusion-positive, 357 wild-type) from June 2016 to December 2023, using...

Topics

Join the communities discussing this publication.

• Aged
• Biomarkers, Tumor
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Neuregulin-1